In the absence of an approved product, investors’ focus will be on the progress of Zynerba Pharmaceuticals, Inc.’s lead pipeline candidate when it reports second-quarter 2019 results.
The company’s earnings beat the Zacks Consensus Estimate in three of the last four quarters and missed the same once, with the average positive surprise being 13.18%.
Shares of Zynerba have surged 273.7% so far this year against the industry‘s decline of 4.2%.
In the last reported quarter, Zynerba came up with a positive earnings surprise of 34.33%.
Let’s see how things are shaping up for this announcement.
Things to Watch Out For
Zynerba is focused on developing cannabinoid therapies for rare neuropsychiatric disorders.
The company is developing Zygel, a cannabidiol, targeting multiple neuropsychiatric indications including Fragile X syndrome (“FXS”), autism spectrum disorder, and developmental and epileptic encephalopathies.
A pivotal study is evaluating the candidate for treating patients with FXS aged 3 to 17 years. Data from the study presented earlier showed improvement in core emotional and behavioral symptoms of statistical significance. Zynerba expects to report top-line data in the second half of this year and submit a new drug application next year. The company may provide an update on the progress of the study on its earnings call. In May, the candidate was granted Fast Track designation for FXS.
In May, the company initiated a phase II study to evaluate Zygel as a treatment for 22q11.2 deletion syndrome, a genetic disorder, which may lead to mental illness.
These ongoing studies are likely to drive operating expenses higher in the soon-to-be reported quarter.
Earnings Whispers
Our proven model does not conclusively show that Zynerba is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Zynerba’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 50 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Zynerba’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
In the absence of an approved product, investors’ focus will be on the progress of Zynerba Pharmaceuticals, Inc.’s lead pipeline candidate when it reports second-quarter 2019 results.
The company’s earnings beat the Zacks Consensus Estimate in three of the last four quarters and missed the same once, with the average positive surprise being 13.18%.
Shares of Zynerba have surged 273.7% so far this year against the industry‘s decline of 4.2%.
In the last reported quarter, Zynerba came up with a positive earnings surprise of 34.33%.
Let’s see how things are shaping up for this announcement.
Things to Watch Out For
Zynerba is focused on developing cannabinoid therapies for rare neuropsychiatric disorders.
The company is developing Zygel, a cannabidiol, targeting multiple neuropsychiatric indications including Fragile X syndrome (“FXS”), autism spectrum disorder, and developmental and epileptic encephalopathies.
A pivotal study is evaluating the candidate for treating patients with FXS aged 3 to 17 years. Data from the study presented earlier showed improvement in core emotional and behavioral symptoms of statistical significance. Zynerba expects to report top-line data in the second half of this year and submit a new drug application next year. The company may provide an update on the progress of the study on its earnings call. In May, the candidate was granted Fast Track designation for FXS.
In May, the company initiated a phase II study to evaluate Zygel as a treatment for 22q11.2 deletion syndrome, a genetic disorder, which may lead to mental illness.
These ongoing studies are likely to drive operating expenses higher in the soon-to-be reported quarter.
Earnings Whispers
Our proven model does not conclusively show that Zynerba is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Zynerba’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 50 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Zynerba’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on GILD - FREE
Get the latest research report on AVXL - FREE